Assessment and management of allergic rhinitis: A review and evidence-informed approach for family medicine

Allergic rhinitis is an inflammatory disorder affecting nasal mucosa in response to al-lergen exposure and is commonly assessed and managed in family medicine. In this article, we review new international guidelines on the diagnosis and management of allergic rhinitis and generate evidence-informed recommendations for family medicine doctors.


| INTRODUC TI ON
Allergic rhinitis (AR) is a common condition encountered in family medicine, affecting up to 15% of the pediatric population and approximately 26% of adults in the United Kingdom. 1 Although often mild, its impact can be far-reaching, affecting school and work performance. 1 is characterized by an immunoglobulin E (IgE)-mediated type 1 hypersensitivity response within the nasal mucosa triggered by allergen exposure. 2Recent guidelines from the International Consensus statement on Allergy and Rhinology: Allergic Rhinitis 2023 (ICAR-Allergic Rhinitis 2023) 3 and the British Society of Allergy and Clinical Immunology (BSACI) 1 draw attention to contemporary strategies for diagnosing and managing AR.In this article, we review and generate evidence-informed recommendations for the management of AR in children and adults in family medicine.

| MAKING A D IAG NOS IS
A comprehensive diagnostic approach begins with a thorough history, enquiring about nasal symptoms of congestion and clear rhinorrhea, including onset, duration, triggers, and seasonal variation.Age of onset occurs predominantly in childhood and adolescence, and has been reported in children as young as 12 months. 3e onset of symptoms is often within minutes following exposure to allergens.Common triggers include aeroallergens such as tree pollen, grass pollen, house dust mites, molds, and animal dander. 3Other signs of AR include sneezing and an itchy nose, and if accompanied by allergic conjunctivitis: epiphora and ocular pruritus. 1,2,4Past medical history may include atopic conditions such as eczema and asthma.A family history of atopy is common.
Evaluating the impact on the individual's daily life, including sleep quality and school performance is particularly pertinent in the pediatric population. 3general examination should inspect for stigmata of allergy, such as transverse dorsal nasal crease, open-mouth breathing, and allergic shiners (dark circles under the eyes).Anterior rhinoscopy can be performed by gently lifting the nasal tip upward while inspecting with an otoscope.We recommend a three-point inspection, looking at the anterior septum, inferior turbinate, and nasal floor.This examination aims to identify signs of inflammation: erythema, edema, septal deviation, polyps, hypertrophy, and pale blue discoloration of the inferior turbinate. 5The inferior turbinate (normal anatomical structure on the lateral nasal wall) can be mistaken for a polyp (benign growths extending from inflamed nasal mucosa).However, it is necessary to be able to clinically distinguish between the two to avoid unnecessary concern.A systematic approach is outlined in Table 1.

| WHAT ARE THE D IFFERENTIAL D I AG N OS E S?
The symptoms of AR are often nonspecific, making the differential diagnosis broad.2][3][4] Red flag symptoms that deviate from the typical AR presentation may raise suspicion of an alternative diagnosis: they are listed in

| WHEN IS ALLERG EN TE S TING INDIC ATED?
Practitioners should organize skin prick testing or serum allergenspecific IgE investigations when suspecting a diagnosis of AR.AR can be secondary to outdoor allergens usually linked to seasonal AR (few months a year during pollen season) and indoor allergens commonly linked with perennial AR (all year).Allergens responsible for seasonal AR include pollens from tree, grass, and weed; whereas, perennial AR is commonly triggered by dust mite, animal dander, and molds.Allergen testing plays a role in confirming diagnosis and provides important advice about allergen avoidance. 3Radiological imaging has no role in AR. 3

| PER SONALIZING TRE ATMENT
Developing a treatment plan that is personalized first involves counseling patients that AR is a chronic condition, and that the treatment is  have a bioavailability of <1% making them safe for long-term use. 6utine use of oral decongestants (e.g., Pseudoephedrine hydrochloride) is not recommended for AR. 3 However, for short-term relief, a nasal decongestant (e.g., xylometazoline hydrochloride) can be used. 1,3,4milarly, oral corticosteroids can be used for a brief duration, 1-4 but clinical prescribers should weigh the potential systemic risks associated with their use.An increased risk of adverse effects (e.g., upper gastrointestinal hemorrhage, sepsis, and heart failure) is observed even when oral steroids are used as infrequently as twice in a year. 7 adopting a systematic step-up and step-down approach, akin to the British Thoracic Society/Scottish Intercollegiate Guidelines Network asthma guidelines, we have produced a flowchart (Figure 1) summarizing the management of AR.Treatment responses should be evaluated within 2-4 weeks after commencement.4 Well-controlled AR can also help improve asthma control in those with coexistent disease.8

| WHEN TO REFER FOR S PECIALIS T C ARE?
Consider urgent referral to an ear, nose, and throat (ENT) specialist if there are red flag features (Table 2).ENT surgical teams should be consulted in the presence of structural abnormalities that impair delivery of topical therapy, such as septal deviation or refractory hypertrophy of the inferior turbinates.In cases where symptoms persist despite optimal medical treatment, consider a referral to an allergy specialist for immunotherapy.

| SUMMARY
This article summarizes evidence-informed guidance for the diagnosis and management of AR for family medicine services.Our stepwise approach enables family medicine clinicians to provide patients with a personalized management plan and optimize treatment for AR.

FU N D I N G I N FO R M ATI O N
Faraz Mughal, Doctoral Fellow, is funded by NIHR (300957).The views in this article are those of the authors, and not necessarily those of the NIHR, NHS, or the Department for Health and Social Care.

CO N FLI C T O F I NTE R E S T S TATE M E NT
Aziz Sheikh was a coauthor on the International Consensus statement on Allergy and Rhinology: Allergic Rhinitis 2023.

E TH I C S S TATEM ENT
None.

O RCI D
focused on symptom control.Second is the implementation of allergen avoidance strategies.Patients can be directed to online information about allergen avoidance, for example, at Allergy UK.Third is to ensure the correct technique is followed when administering intranasal therapy.Intranasal saline is recommended as a component of the overall treatment strategy.3Pharmacological treatment options include oral nonsedating antihistamines (e.g., cetirizine, loratadine, and fexofenadine), intranasal antihistamines (e.g., azelastine hydrochloride), and intranasal corticosteroids.Contrary to misconceptions, second-generation intranasal corticosteroids sprays (INCS) (e.g., Avamys, Nasonex, and Flixonase) Mughal https://orcid.org/0000-0002-5437-5962R E FE R E N C E S 1. Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, et al.BSACI guideline for the diagnosis and management of F I G U R E 1 A stepwise approach to the management of AR in family medicine.